Leerink Partners Maintains Outperform on HCA Healthcare, Raises Price Target to $396
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners maintains an Outperform rating on HCA Healthcare and raises the price target from $367 to $396.
July 24, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has maintained its Outperform rating on HCA Healthcare and increased the price target from $367 to $396.
The increase in the price target from $367 to $396 by Leerink Partners, along with the maintained Outperform rating, is a positive signal for investors. This suggests confidence in HCA Healthcare's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100